inetetamab + pyrotinib + dalpiciclib

Cipterbin + pyrotinib + dalpiciclib (inetetamab + pyrotinib + dalpiciclib) is an investigational, chemotherapy-free combination regimen being evaluated for the treatment of HER2-positive advanced or metastatic breast cancer. The regimen combines three targeted agents: inetetamab (Cipterbin), an Fc-engineered anti-HER2 monoclonal antibody designed for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC); pyrotinib, an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) targeting EGFR (HER1), HER2, and HER4; and dalpiciclib, an oral, selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. By simultaneously blocking extracellular HER2 signaling, intracellular ErbB kinase activity, and downstream cell cycle progression via the CDK4/6-retinoblastoma pathway, this triplet regimen aims to overcome resistance to standard anti-HER2 therapies and provide a synergistic antitumor effect. The combination is primarily being developed and studied in China, notably in clinical trials such as the phase II DAP-HER2-02 study.